This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, D. Articles by the Breast Cancer Linkage Consortium Search for Related Content PubMed PubMed Citation Articles by Thompson, D. Articles by the Breast Cancer Linkage Consortium,

Variation in BRCA1 Cancer Risks by Mutation Position¹

Cancer Research Campaign Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Cambridge CB1 8RN, United Kingdom

Previous studies have reported variation in BRCA1 breast and ovarian cancer risks with mutation position, suggesting that mutations toward the 3' end of the gene are associated with lower ovarian cancer risks. We evaluated the evidence for genotype-phenotype correlations in 356 families with protein-truncating BRCA1 mutations. In contrast to previous reports, the ovarian:breast cancer ratio associated with mutations in a central region of the gene (nucleotides 2401–4190) was significantly higher than for other mutations [odds ratio, 1.70 (P = 0.017) compared with nucleotides 1–2400; odds ratio, 1.89 (P = 0.02) compared with nucleotides 4191–end]. The risks of breast and ovarian cancer conferred by mutations in different regions of the gene were estimated separately by conditional maximum likelihood. According to the best fitting model, the breast cancer risk associated with mutations in the central region was found to be significantly lower than for other mutations (relative risk, 0.71; 95% confidence interval, 0.58–0.86; P = 0.0002), whereas the ovarian cancer risk associated with mutations 3' to nucleotide 4191 was significantly reduced relative to the rest of the gene (relative risk, 0.81; 95% confidence interval, 0.66–1.00; P = 0.044). The cancer risks associated with missense mutations in the RING domain in exon 5 appear to be similar to those associated with protein-truncating mutations toward the 3' end of BRCA1, based on nine additional families.

This article has been cited by other articles:

				M. D. Palma, S. M. Domchek, J. Stopfer, J. Erlichman, J. D. Siegfried, J. Tigges-Cardwell, B. A. Mason, T. R. Rebbeck, and K. L. Nathanson The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families Cancer Res., September 1, 2008; 68(17): 7006 - 7014. [Abstract] [Full Text] [PDF]

				R. L. Milne, A. Osorio, T. R. y Cajal, A. Vega, G. Llort, M. de la Hoya, O. Diez, M. C. Alonso, C. Lazaro, I. Blanco, et al. The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain Clin. Cancer Res., May 1, 2008; 14(9): 2861 - 2869. [Abstract] [Full Text] [PDF]

				C. B. Begg, R. W. Haile, A. Borg, K. E. Malone, P. Concannon, D. C. Thomas, B. Langholz, L. Bernstein, J. H. Olsen, C. F. Lynch, et al. Variation of Breast Cancer Risk Among BRCA1/2 Carriers JAMA, January 9, 2008; 299(2): 194 - 201. [Abstract] [Full Text] [PDF]

				H. A. Risch, J. R. McLaughlin, D. E. C. Cole, B. Rosen, L. Bradley, I. Fan, J. Tang, S. Li, S. Zhang, P. A. Shaw, et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada J Natl Cancer Inst, December 6, 2006; 98(23): 1694 - 1706. [Abstract] [Full Text] [PDF]

				M. de la Hoya, S. Gutierrez-Enriquez, E. Velasco, A. Osorio, A. S. de Abajo, A. Vega, R. Salazar, E. Esteban, G. Llort, R. Gonzalez-Sarmiento, et al. Genomic Rearrangements at the BRCA1 Locus in Spanish Families with Breast/Ovarian Cancer Clin. Chem., August 1, 2006; 52(8): 1480 - 1485. [Abstract] [Full Text] [PDF]

				J Gronwald, T Huzarski, B Byrski, K Medrek, J Menkiszak, A N Monteiro, P Sun, J Lubinski, and S A Narod Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status J. Med. Genet., May 1, 2006; 43(5): 424 - 428. [Abstract] [Full Text] [PDF]

				B Gorski, J Menkiszak, J Gronwald, J Lubinski, and S A Narod A protein truncating BRCA1 allele with a low penetrance of breast cancer J. Med. Genet., December 1, 2004; 41(12): e130 - e130. [Full Text] [PDF]

				A. Liede, B. Y. Karlan, and S. A. Narod Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature J. Clin. Oncol., February 15, 2004; 22(4): 735 - 742. [Abstract] [Full Text] [PDF]

				F. Modugno Ovarian Cancer and Polymorphisms in the Androgen and Progesterone Receptor Genes: A HuGE Review Am. J. Epidemiol., February 15, 2004; 159(4): 319 - 335. [Abstract] [Full Text] [PDF]

				P. Hohenstein and R. Fodde Of mice and (wo)men: genotype-phenotype correlations in BRCA1 Hum. Mol. Genet., October 15, 2003; 12(90002): R271 - 277. [Abstract] [Full Text] [PDF]

				H. M. Klaren, L. J. van't Veer, F. E. van Leeuwen, and M. A. Rookus Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation J Natl Cancer Inst, July 2, 2003; 95(13): 941 - 947. [Full Text] [PDF]

				S. M. Ginolhac, S. Gad, M. Corbex, B. Bressac-de-Paillerets, A. Chompret, Y.-J. Bignon, J.-P. Peyrat, J. Fournier, C. Lasset, S. Giraud, et al. BRCA1 Wild-Type Allele Modifies Risk of Ovarian Cancer in Carriers of BRCA1 Germ-Line Mutations Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 90 - 95. [Abstract] [Full Text] [PDF]

				H. A. Risch and S. A. Narod Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance J Natl Cancer Inst, January 1, 2003; 95(1): 73 - 74. [Full Text] [PDF]

				L. Perrin-Vidoz, O. M. Sinilnikova, D. Stoppa-Lyonnet, G. M. Lenoir, and S. Mazoyer The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons Hum. Mol. Genet., November 1, 2002; 11(23): 2805 - 2814. [Abstract] [Full Text] [PDF]

				D. Thompson, D. F. Easton, and the Breast Cancer Linkage Consortium Cancer Incidence in BRCA1 Mutation Carriers J Natl Cancer Inst, September 18, 2002; 94(18): 1358 - 1365. [Abstract] [Full Text] [PDF]

				M. S. Brose, T. R. Rebbeck, K. A. Calzone, J. E. Stopfer, K. L. Nathanson, and B. L. Weber Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program J Natl Cancer Inst, September 18, 2002; 94(18): 1365 - 1372. [Abstract] [Full Text] [PDF]